
Jie Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1609016/publications.pdf Version: 2024-02-01



LE FENC

#	Article	IF	CITATIONS
1	Inter-hemispheric Functional Connections Are More Vulnerable to Attack Than Structural Connection in Patients With Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2021, 27, 426-435.	0.8	6
2	Peroral endoscopic myotomy for esophageal motility disorders. Esophagus, 2020, 17, 11-18.	1.0	17
3	Phylogenetic supertree reveals detailed evolution of SARS-CoV-2. Scientific Reports, 2020, 10, 22366.	1.6	39
4	The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials. Annals of Palliative Medicine, 2020, 9, 883-894.	0.5	7
5	Could CTSK and COL4A2 be specific biomarkers of poor prognosis for patients with gastric cancer in Asia?—a microarray analysis based on regional population. Journal of Gastrointestinal Oncology, 2020, 11, 386-401.	0.6	6
6	Prognostic and Predictive Value of Cadherin 11 for Patients with Gastric Cancer and Its Correlation with Tumor Microenvironment: Results from Microarray Analysis. BioMed Research International, 2020, 2020, 1-16.	0.9	6
7	Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of B. burgdorferi. Frontiers in Medicine, 2020, 7, 6.	1.2	22
8	Identification of a novel gene argJ involved in arginine biosynthesis critical for persister formation in Staphylococcus aureus. Discovery Medicine, 2020, 29, 65-77.	0.5	0
9	Identification of Genes Regulating Cell Death in Staphylococcus aureus. Frontiers in Microbiology, 2019, 10, 2199.	1.5	7
10	Correct anemia or prevent acute myocardial infarction in patients on maintenance hemodialysis?. Renal Failure, 2019, 41, 883-884.	0.8	0
11	Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae. Antibiotics, 2019, 8, 50.	1.5	15
12	Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. Discovery Medicine, 2019, 27, 125-138.	0.5	36
13	Infection with persister forms of Staphylococcus aureus causes a persistent skin infection with more severe lesions in mice: failure to clear the infection by the current standard of care treatment. Discovery Medicine, 2019, 28, 7-16.	0.5	6
14	Identification of Essential Oils with Strong Activity against Stationary Phase Borrelia burgdorferi. Antibiotics, 2018, 7, 89.	1.5	41
15	A Rapid Growth-Independent Antibiotic Resistance Detection Test by SYBR Green/Propidium Iodide Viability Assay. Frontiers in Medicine, 2018, 5, 127.	1.2	24
16	Varying effects of common tuberculosis drugs on enhancing clofazimine activity <i>in vitro</i> . Emerging Microbes and Infections, 2017, 6, 1-3.	3.0	7
17	Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library. Emerging Microbes and Infections, 2017, 6, 1-3.	3.0	5
18	Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro. Antibiotics, 2017, 6, 10.	1.5	15

Jie Feng

#	Article	IF	CITATIONS
19	Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia burgdorferi. Frontiers in Medicine, 2017, 4, 169.	1.2	43
20	Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. Frontiers in Microbiology, 2016, 7, 62.	1.5	30
21	A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library. Frontiers in Microbiology, 2016, 7, 743.	1.5	49
22	Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony B. burgdorferi Persisters Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing. Frontiers in Microbiology, 2016, 7, 1744.	1.5	25
23	Assessment of photosynthesis regulation in mixotrophically cultured microalga Chlorella sorokiniana. Algal Research, 2016, 19, 30-38.	2.4	44
24	A Clinical Drug Library Screen Identifies Tosufloxacin as Being Highly Active against Staphylococcus aureus Persisters. Antibiotics, 2015, 4, 329-336.	1.5	21
25	Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library. Antibiotics, 2015, 4, 397-410.	1.5	43
26	Genetic Screen Reveals the Role of Purine Metabolism in Staphylococcus aureus Persistence to Rifampicin. Antibiotics, 2015, 4, 627-642.	1.5	64
27	Drug Combinations against Borrelia burgdorferi Persisters In Vitro: Eradication Achieved by Using Daptomycin, Cefoperazone and Doxycycline. PLoS ONE, 2015, 10, e0117207.	1.1	111
28	Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics, 2015, 4, 179-187.	1.5	29
29	Regulation of starch and lipid accumulation in a microalga Chlorella sorokiniana. Bioresource Technology, 2015, 180, 250-257.	4.8	110
30	Persister mechanisms in <i>Borrelia burgdorferi</i> : implications for improved intervention. Emerging Microbes and Infections, 2015, 4, 1-3.	3.0	31
31	Identification of new compounds with high activity against stationary phase <i>Borrelia burgdorferi</i> from the NCI compound collection. Emerging Microbes and Infections, 2015, 4, 1-15.	3.0	42
32	An Optimized SYBR Green I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for Borrelia burgdorferi. PLoS ONE, 2014, 9, e111809.	1.1	92
33	Identification of novel activity against <i>Borrelia burgdorferi</i> persisters using an FDA approved drug library. Emerging Microbes and Infections, 2014, 3, 1-8.	3.0	99
34	Aspartate decarboxylase (PanD) as a new target of pyrazinamide in <i>Mycobacterium tuberculosis</i> . Emerging Microbes and Infections, 2014, 3, 1-8.	3.0	122
35	Proteomic Analysis of the Secretome of Haloarchaeon <i>Natrinema</i> sp. J7–2. Journal of Proteome Research, 2014, 13, 1248-1258.	1.8	15
36	The Complete Genome Sequence of Natrinema sp. J7-2, a Haloarchaeon Capable of Growth on Synthetic Media without Amino Acid Supplements. PLoS ONE, 2012, 7, e41621.	1.1	31